199328-34-2

Basic information

• Product Name: Propanedioic acid, (4-bromo-2-nitrophenyl)-, diethyl ester
• CAS NO: 199328-34-2
• Molecular Formula: C13H14BrNO6
• Molecular Weight: 360.161
• Mol File: 199328-34-2.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: Propanedioic acid, (4-bromo-2-nitrophenyl)-, diethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Propanedioic acid, (4-bromo-2-nitrophenyl)-, diethyl ester(199328-34-2)
• EPA Substance Registry System: Propanedioic acid, (4-bromo-2-nitrophenyl)-, diethyl ester(199328-34-2)

Safety Data

• Hazardous Substances Data: 199328-34-2(Hazardous Substances Data)

Upstream product

• 3460-18-2 1,4-dibromo-2-nitrobenzene 
• 105-53-3 diethyl malonate 
• 51686-78-3 2,4-dibromonitrobenzene 

Downstream Products

• 99365-40-9 6-bromo-2,3-dihydro-1H-indole-2-one 
• 1098855-11-8 C₉H₆BrNO₆ 
• 199328-35-3 ethyl 2-(4-bromo-2-nitrophenyl)acetate 
• 6127-11-3 (4-bromo-2-nitrophenyl)acetic acid 

Relevant articles and documents

Polymer based on benzothiadiazole-bridged bis-isoindigo for organic field-effect transistor applications

Two isoindigos were symmetrically connected by 2,1,3-benzothiadiazole core to form an acceptor2-acceptor1-acceptor2 monomer. The new monomer was used as electron acceptor unit in construction of a unique donor/acceptor polymer with donor-acceptor2-accepto

SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF FIELD OF THE INVENTION

A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.

HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS

Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R' have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors,in HCV therapy.